Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Previous or coincident infections with suspected Kawasaki disease. Should we change our approach?∗, ∗∗

Elisa Fernández-Cooke a,∗, Ana Barrios Tascón b, Jordi Antón-López c, Carlos Daniel Grasa Lozano a, Judith Sánchez-Manubens c, Cristina Calvo d, on behalf of the Working Group for the Study of Kawasaki Disease (KAWA-RACE)

a Servicio de Pediatría, Hospital 12 de Octubre, Madrid, Spain
b Servicio de Pediatría, Hospital Infanta Sofía, San Sebastián de los Reyes (Madrid), Spain
c Servicio de Pediatría, Hospital Sant Joan de Déu, Esplugues de Llobregat (Barcelona), Spain
d Servicio de Pediatría, Hospital Universitario La Paz, Madrid, Spain

Received 26 February 2018; accepted 25 June 2018
Available online 8 March 2019

KEYWORDS
Kawasaki disease; Vasculitis; Coronary aneurysm

Abstract
Introduction: Kawasaki disease (KD) is a multisystem vasculitis associated with coronary artery abnormalities. Infections could be a trigger of the inflammation. The main aim of this study was to describe the presence of infections in children with KD, and to analyse the clinical characteristics and the presence of coronary abnormalities in these cases.

Patients and methods: A retrospective study was performed within the Kawasaki Disease network (KAWA-RACE 2011-2016). An analysis was performed that included patients with positive microbiological findings (PMF) during the acute phase, as well as those with a previous recent infection (PRI) during the 4 weeks preceding KD diagnosis.

Results: The study included a total of 621 children with KD, with PMF being found in 101 (16.3%) patients, and a PRI in 107 (17.2%). Significantly less echocardiographic abnormalities were found in the group with a PRI, when compared to those without a PRI (23 vs. 35%, P = .01) and also a lower proportion of overall coronary artery lesions (16 vs. 25%, P = .054). No significant differences were found in the proportion of aneurysms in either of these groups (PRI or PMF) when compared to those without infection.

∗ Please cite this article as: Fernández-Cooke E, Tascón AB, Antón-López J, Grasa Lozano CD, Sánchez-Manubens J, Calvo C, et al. Infecciones previas o coincidentes con la sospecha de enfermedad de Kawasaki ¿debemos cambiar nuestra actitud? An Pediatr (Barc). 2019;90:213–218.

∗∗ Previous presentations: abstracts related to this study were submitted for participation in the Congress of the Asociación Española de Pediatría held in June 2018 in Zaragoza, Spain (accepted for oral communications) and the Annual Meeting of the European Society for Paediatric Infectious Diseases held in May 2018 in Malmö, Sweden (accepted for a poster presentation).

∗ Corresponding author.
E-mail address: elisacooke@gmail.com (E. Fernández-Cooke).

2341-2879/© 2018 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Kawasaki disease (KD) is an acute self-limited vasculitis that affects small- and medium-size vessels and usually develops in early childhood. At present it is the most common cause of acquired heart disease in the Spanish paediatric population.\(^1,2\) Its incidence in Europe is of approximately 8 per 100,000 children under 5 years.\(^1,4\) Although the clinical manifestations, laboratory findings and epidemiological characteristics of the disease suggest an infectious trigger, the causative agent has yet to be identified.\(^3,6\) A few genome-wide association studies (GWAS) on KD have been published that identified several plausible candidate loci involved in inflammation, the immune response and cardiovascular abnormalities.\(^7,8\) Thus, a reasonably broad hypothesis is that KD is caused by an infectious agent yet to be identified that only causes disease in individuals with a genetic predisposition. Its rarity in the first months of life and in adults suggests that this is a pathogen that these collectives are immune to, with very young infants being protected by passive immunity through maternal antibodies.

Kawasaki disease is a clinical diagnosis that is determined based on the diagnostic criteria proposed by the American Heart Association (AHA).\(^2\) The presence of a previous or concurrent infection, especially with microbiological confirmation, can be considered an alternative diagnosis that rules out KD. This aspect is currently under debate. The aim of our study was to assess the presence of previous or concurrent infection in children with a diagnosis of KD based on data collected by the Spanish network for the study of this illness (KAWA-RACE), and its association with the presence of coronary artery abnormalities.

Patients and methods

In 2015, a nationwide paediatric network was created in Spain for the purpose of researching KD (the KAWA-RACE network) with the support of the Sociedad Española de Infectología Pediátrica (Spanish Society of Paediatric Infectious Diseases [SEIP]), Sociedad Española de Reumatología Pediátrica (Spanish Society of Paediatric Rheumatology [SERPE]) and the Sociedad Española de Cardiología Pediátrica y Cardiopatías Congénitas (Spanish Society of Paediatric Cardiology and Congenital Heart Diseases [SECPPC]). A total of 53 Spanish hospitals from all regions in the country participated, collecting epidemiological, clinical and treatment data on patients in an online database (REDcap).\(^1\) We conducted a retrospective study covering the 2011–2016 period, including patients aged less than 16 years that received a diagnosis of KD based on the AHA criteria\(^10\) in
any of the participating hospitals. The study was approved by the Ethics Committee.

We used the following definitions:

- Recent previous infection (RPI): infection diagnosed in the 4 weeks preceding the diagnosis of KD, without need of a positive microbiological test to confirm the infection.
- Microbiologically-confirmed infection (MCI): infection diagnosed during the acute phase of KD with a positive microbiological test.

We defined echocardiographic abnormality as evidence of any type of cardiovascular involvement, including the presence of valvular insufficiency, pericarditis, signs of myocarditis or coronary artery abnormalities. Coronary artery abnormalities included the presence of hyperechoic lesions, dilatation or coronary aneurysms defined according to the AHA criteria.2

Statistical analysis

We performed the statistical analysis with the Statistical Package for the Social Sciences (SPSS) version 20.0. We have expressed discrete data as percentages and continuous data as mean and standard deviation (SD). We compared clinical and laboratory characteristics and the presence of coronary artery abnormalities in patients with and without RPI or MCI. The tests used for comparing clinical characteristics and laboratory findings were the Student t test, Mann–Whitney U test, χ² test and Fisher exact test as appropriate. We defined statistical significance as a p-value of less than 0.05.

Results

The study included a total of 621 patients with KD. Sixty-three percent were male. The mean age at diagnosis was 2.8 years (SD, 2.4); 494 (79.5%) were aged less than 5 years. Of all cases, 437 were classified as complete KD (70.4%), 171 as incomplete KD (27.5%) and 13 as atypical (2.1%). There was evidence of coronary artery abnormalities in 60 cases (9.7%), which were persistent in 28 cases (4.5%).

Recent previous infections

Of the 621 patients, 107 (17.2%) reported a RPI. These infections were most frequent in spring (38%; P = .023). We found no differences between patients with RPI and patients without in sex, age, type of KD, laboratory findings, total duration of fever or need of a second dose of intravenous immunoglobulin (Table 1). Of the 5 principal clinical features, we found differences in the presence of lymphadenopathy, which was more frequent in the RPI group (76% vs 64%; P = .01). We found a lower prevalence of echocardiographic abnormalities in the RPI group that was statistically significant (23 vs 35%; P = .01) as well as a lower proportion of coronary abnormalities, although this difference was not significant (16% vs 25%; P = .054). There were no differences in the presence of aneurysms.

The RPI documented most frequently were: ear-nose-throat (ENT) involvement, mainly pharyngitis (n = 65; 61%), gastroenteritis (n = 12; 11%), acute otitis media (n = 7; 7%), urinary tract infection (n = 6; 6%), scarlatiniform rash (n = 5; 5%) and skin and soft tissue infections (n = 3; 3%). Patients whose previous infection involved ENT involvement had coronary artery aneurysms in 10.5% of cases, a proportion that was higher compared to the rest of patients with a RPI (7%; P = .051).

Microbiologically confirmed infections

We identified 101 cases (16.3%) of patients with a MCI; 9 of them had several infections and 4 presented with viral coinfection (Table 2). Microbiologically confirmed infections were most frequent in spring (34% of the total; P = .07). Patients with MCI did not differ from patients with no microbiological confirmation of infection in sex, age, type of KD, clinical diagnostic criteria, total duration of fever or need of a second dose of intravenous immunoglobulin (Table 1). We found significantly higher erythrocyte sedimentation rates in the MCI group (83 vs 72 mm/h). We did not find differences in the frequency of echocardiographic abnormalities overall or in the frequency of coronary artery abnormalities or aneurysms.

Discussion

Our study evinces that recent or concurrent infections are common in KD and do not decrease the risk of developing coronary artery aneurysms. The presence of a RPI has also been described in the literature.5,6,11 Weng et al. conducted a population-based study where they followed up 285 636 children with infection by enterovirus and 285 636 children without this infection, and found that the incidence of KD was 54% greater in the infected group compared to the group without infection.5

The clinical manifestations of many of the most frequent infections in the paediatric population overlap the clinical features used to define KD, which complicates its diagnosis.2 In our case series, we found 65 patients (10.5%) with a history of ENT infection and 6 patients (1%) with a scarlatiniform rash, both infections whose manifestations overlap with the principal clinical features of KD. There were also 12 patients with gastroenteritis (2%), and previous studies in the literature have reported that KD may present with symptoms compatible with gastroenteritis,1,9 including a study conducted in Spain by Sánchez-Manubens et al that found them in as many as 24% of the patients.3

Historically, there has been concern that KD may be overdiagnosed.12 In our study we found a lower incidence of cardiac complications in the group of patients with a history of RPI, which may suggest that KD is also overdiagnosed in Spain,2 but we did not find differences in the presence of aneurysms.

In our cohort, the proportion of coronary artery involvement and more specifically of coronary artery aneurysms (7%–10%) was high compared to Asian case series in Japan (0.91%), Korea (1.7%) and Shanghai (1.1%), lower compared to the frequency reported in the United States (13%) and some European countries, such as the Netherlands (13.5%) or Germany (17%), but similar to the prevalence reported in case series of other neighbouring countries, such as Portugal.
Some frequency complications for KD, we have minimised the risk of cardiovascular lesions that are clinically relevant with the aim of maximising benefits and minimising harm in these children.

The fact that lymphadenopathy was more frequent in the RPI group and that this feature is a criterion for the diagnosis of KD could contribute to the potential overdiagnosis of the disease in patients that do not actually have it. Thus, our findings evince that the diagnosis of KD continues to pose a significant challenge. Considering the risk of cardiac complications associated with not treating a true case of KD, we believe that utmost caution and rigour should be exercised when advising against treatment, especially in the groups at highest risk, which include infants and severely ill patients.

When it comes to the presence of concurrent infections, many studies in the literature have pointed at different viruses as triggers of KD, including coxsackie virus, parainfluenza virus, respiratory syncytial virus, metapneumovirus, chikungunya virus, cytomegalovirus and enterovirus, among others. Some studies have reported positive detection of one or more respiratory viruses by PCR in up to half of the patients with KD, although their pathogenic role is not clear. Chang et al selected 226 children with KD and 226 healthy children and performed PCR tests and cultures for detection of respiratory viruses in respiratory secretions. They found viruses in 50.4% of the ill children compared to 16.4% of healthy children (P < .001) and concluded that viral infections are associated with KD.

On the other hand, we cannot overlook the nature of viral infections and the possibility that an individual remain an asymptomatic carrier for a variable period of time.

### Table 1: Epidemiological, clinical and laboratory characteristics of patients with Kawasaki disease based on the presence or absence of microbiologically confirmed infection and of a history of infection in the 4 weeks preceding diagnosis.

| Epidemiological and clinical characteristics | Positive microbiological identification (n = 101) | No microbiological identification (n = 520) | P | Recent previous infection (n = 107) | No recent previous infection (n = 514) | P |
|-----------------------------------------------|-----------------------------------------------|------------------------------------------|---|-----------------------------------|--------------------------------------|---|
| Male sex, n (%)                               | 61 (61)                                       | 330 (64)                                 | .62| 67 (63)                           | 324 (63)                             | .54|
| Age < 12 months                               | 15 (16)                                       | 88 (18)                                  | .65| 16 (16)                           | 87 (18)                              | .68|
| Complete KD, n (%)                            | 72 (71)                                       | 365 (70)                                 | .97| 77 (72)                           | 360 (70)                             | .64|
| Conjunctival injection, n (%)                 | 83 (83)                                       | 444 (86)                                 | .37| 90 (85)                           | 437 (86)                             | .76|
| Oral changes, n (%)                           | 93 (93)                                       | 468 (91)                                 | .52| 99 (93)                           | 462 (91)                             | .41|
| Extremity involvement, n (%)                  | 70 (71)                                       | 372 (74)                                 | .54| 75 (71)                           | 367 (74)                             | .65|
| Exanthema, n (%)                              | 83 (84)                                       | 443 (87)                                 | .34| 92 (89)                           | 434 (87)                             | .58|
| Lymphadenopathy, n (%)                        | 67 (68)                                       | 332 (65)                                 | .65| 80 (76)                           | 319 (64)                             | .01|
| Duration of fever (days), mean ± SD          | 8.57 ± 3.92                                   | 8.38 ± 3, 67                             | .64| 8.35 ± 4.02                       | 8.43 ± 3.64                          | .83|
| Days from onset of fever to IVIG, mean ± SD  | 7.88 ± 6.87                                   | 7.04 ± 3.84                              | .10| 6.69 ± 3.02                       | 7.30 ± 4.77                          | .23|
| ESR (mm/h), mean ± SD                         | 83 ± 34                                       | 72 ± 34                                  | .01| 78 ± 32                           | 73 ± 35                              | .23|
| CRP (mg/dL), mean ± SD                        | 46 ± 70                                       | 35 ± 61                                  | .12| 34 ± 57                           | 37 ± 64                              | .59|
| AST (IU/L), mean ± SD                         | 88 ± 18                                       | 75 ± 6                                   | .42| 63 ± 7                            | 80 ± 7                               | .20|
| ALT (IU/L), mean ± SD                         | 102 ± 13                                      | 84 ± 6                                   | .20| 71 ± 9                            | 80 ± 6                               | .2  |
| White blood cell count (cells × 10³/L), mean ± SD | 18.073 ± 6.210                            | 17.911 ± 7.745                           | .84| 18.298 ± 6.553                    | 17.870 ± 7.631                      | .63|
| Neutrophil count, (cells × 10⁹/L), mean ± SD  | 11.950 ± 5.005                                | 11.918 ± 6.141                           | .96| 12.478 ± 5.796                    | 11.808 ± 5.955                      | .35|
| ECHO abnormalities, n (%)                     | 32 (34)                                       | 165 (33)                                 | .85| 24 (23)                           | 173 (35)                             | .01|
| Coronary abnormalities, n (%)                 | 20 (20)                                       | 123 (24)                                 | .40| 17 (16)                           | 126 (25)                             | .054|
| Aneurysm, n (%)                               | 9 (9)                                         | 50 (10)                                  | .82| 7 (7)                             | 52 (10)                              | .25|
| Administration of a 2nd dose of IVIG, n (%)   | 19 (19)                                       | 79 (16)                                  | .49| 19 (19)                           | 79 (16)                              | .46|

Statistically significant differences are presented in boldface.

ALT, alanine transaminase; AST, aspartate transaminase; CRP, C-reactive protein; ECHO, echocardiography; ESR, erythrocyte sedimentation rate; IVIG, intravenous immunoglobulin; SD, standard deviation.
Table 2. Positive microbiological results obtained in patients with Kawasaki disease (KAWA-RACE network, 2011–2016).

| Test Type                                      | Number of tests | Positive tests | Distribution of results |
|-----------------------------------------------|-----------------|----------------|-------------------------|
| Viral testing in nasopharyngeal aspirate sample | 245             | 35             | Adenovirus (9), influenza virus (9), rhinovirus (7), RSV (4), herpes simplex virus (4), parainfluenza virus (2), coronavirus (1), SGA (29), Staphylococcus aureus (1), Pseudomonas aeruginosa (1), Haemophilus influenzae (1), Kingella kingae (1), other streptococci (1) |
| Bacterial testing in throat swab sample       | 266             | 34             | Escherichia coli (10), Proteus mirabilis (3), Enterococcus faecalis (2), Morganella morganii (1) |
| Urine culture                                 | 273             | 16             | Rotavirus (9), adenovirus (3), dysbacteriosis (2), Mycoplasma pneumoniae (2), parvovirus (3), EBV (2), CMV (2), Chlamydia pneumoniae (1) |
| Stool culture                                 | 109             | 14             | Staphylococcus aureus and Streptococcus pneumoniae in a single patient |
| Serologic testingb                            | 7               |                | Enterovirus |
| Blood culture                                 | 438             | 16             | Skin secretion sample for testing of Staphylococcus aureus (1), positive CMV PCR in urine (1) |
| Lumbar puncture                               | 29              | 1              | |
| Other                                         | 2               |                | |

CMV, cytomegalovirus; EBV, Epstein-Barr virus; GAS, group A streptococcus; PCR, polymerase chain reaction; RSV, respiratory syncytial virus.

Four patients had viral coinfection.

b The number of patients in whom serologic tests were performed was unknown.

following a viral infection. One such example is infection by adenovirus, whose symptoms overlap with those of KD and which happens to cause significant elevation of acute phase reactants in laboratory tests, as we observed in patients in our series. Jaggi et al.16 reported detection of adenovirus in the throat of patients with complete and incomplete KD and in healthy individuals, and found that in patients with complete KD, the viral load was significantly lower compared to patients with incomplete KD, which led them to conclude that a positive test result for adenovirus should be interpreted with caution, as it could indicate a current infection by adenovirus in a patient that meets the criteria for KD or that a patient with KD is also an asymptomatic carrier of adenovirus.

Even if viruses are isolated from patients during the acute phase of KD, previous data have shown no differences in the incidence of coronary artery abnormalities in these patients compared to those that do not have viral infection, as was the case in our cohort. In our study, 35 patients (5.6%) tested positive for respiratory viruses, a significantly lower figure, but it must be taken into account that nasopharyngeal aspirate samples were obtained for viral detection in only 245 patients (39%), and that not all hospitals tested patients by means of respiratory virus PCR panels. The retrospective nature of our study and the absence of a shared protocol for microbiological diagnosis constitute the main limitations of this study. To establish the actual incidence of infection in patients with KD, the same microbiological tests would need to be performed in all patients, but there is not a standard protocol for testing and even the most recent guidelines of the AHA, from 2017, recommend individualised testing based on the judgement of the clinician and the symptoms of the patient.

In short, based on our findings and those of previous studies, the presence of concurrent infection does not rule out the diagnosis of KD, which challenges the hypothesis that KD is overdiagnosed.

In conclusion, we did not find differences in the incidence of cardiac complications in patients with and without microbiological confirmation of infection, and therefore treatment should be initiated whenever there is suspicion of KD, whether or not infection is suspected or confirmed by a positive microbiological test. In our case series, recent previous infections were associated with a lower incidence of coronary abnormalities in patients with a KD diagnosis, although the incidence of coronary aneurysms was not lower in this group. It appears that high-quality prospective studies will be required to establish the role of infection in KD. We hope that the prospective recruitment already underway though the KAWA-RACE network, which we encourage every hospital in Spain to join, will contribute to elucidating this matter.

Funding

The KAWA-RACE group received a research grant from the Sociedad Española de Reumatología Pediatrónica (SERPE) in the 2015 competition. These funds were devoted to the development of the working group and administrative expenditures.

Conflicts of interest

The authors have no conflicts of interest to declare.
Acknowledgments

We thank all the researchers in the KAWA-RACE working group for their participation and contribution of patient information.

References

1. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MCLS) prevailing in Japan. Pediatrics. 1974;54:271–6.
2. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927–99.
3. Sánchez-Manubens J, Antón J, Bou R, Iglesias E, Calzada-Hernandez J. Incidence, epidemiology and clinical features of Kawasaki disease in Catalonia, Spain. Clin Exp Rheumatol. 2016;34:5139–44.
4. Chang LY, Lu CY, Shao PL, Lee PI, Lin MT, Fan TY. Viral infections associated with Kawasaki disease. J Formos Med Assoc. 2014;113:148–54.
5. Weng KP, Wei JC, Hung YM, Huang SH, Chien KJ, Lin CC, et al. Enterovirus infection and subsequent risk of Kawasaki disease: a population-based cohort study. Pediatr Infect Dis J. 2018;37:310–5, http://dx.doi.org/10.1097/INF.0000000000001748.
6. Turnier JL, Anderson MS, Heizer HR, Jone PN, Glodé MP, Dominguez SR. Concurrent respiratory viruses and Kawasaki disease. Pediatrics. 2015;136:e609–14.
7. Witt MT, Minich LL, Bohnsack JF, Young PC. Kawasaki disease: more patients are being diagnosed who do not meet American Heart Association criteria. Pediatrics. 1999;104:e10.
8. Makino N, Nakamura Y, Yashiro M, Sano T, Ae R, Kosami K, et al. Descriptive epidemiology of Kawasaki disease in Japan, 2011–2012: from the results of the 22nd nationwide survey. J Epidemiol. 2015;25:239–45.
9. Kim GB, Park S, Eun LY, Han JW, Lee SY, Yoon KL, et al. Epidemiology and clinical features of Kawasaki disease in South Korea, 2012–2014. Pediatr Infect Dis J. 2017;36:482–5.
10. Chen J-J, Ma X-J, Liu F, Yan WL, Huang MR, Huang M, et al. Epidemiologic features of Kawasaki disease in Shanghai from 2008 through 2012. Pediatr Infect Dis J. 2016;35:7–12 http://www.ncbi.nlm.nih.gov/pubmed/26372452.
11. Okubo Y, Nochioka K, Sakakibara H, Testa M, Sundel RP. National survey of pediatric hospitalizations due to Kawasaki disease and coronary artery aneurysms in the USA. Clin Rheumatol. 2017;36:413–9, http://dx.doi.org/10.1007/s10067-016-3512-6. Epub 2016 Dec 16.
12. Tacke CE, Breunis WB, Pereira RR, Breur JM, Kuipers IM, Kuipers TW. Five years of Kawasaki disease in the Netherlands: a national surveillance study. Pediatr Infect Dis J. 2014;33:793–7.
13. Jakob A, Whelan J, Kordecki M, Berner R, Stiller B, Arnold R, et al. Kawasaki disease in Germany. Pediatr Infect Dis J. 2016;35:129–34.
14. Pinto FF, Laranjo S, Carmo MM, Brito AJ, Ferreira RC. Twelve years of Kawasaki disease in Portugal. Pediatr Infect Dis J. 2016;36;1.
15. Platt MW. Overdiagnosis and child health. Arch Dis Child. 2018, http://dx.doi.org/10.1136/archdischild-2018-314847, pii:archdischild-2018-314847 [Epub ahead of print].
16. Jaggi P, Kajon AE, Mejias A, Ramilo O, Leber A. Human adenovirus infection in Kawasaki disease: a confounding bystander? Clin Infect Dis. 2013;56:58–64.